申请人:——
公开号:US20040121940A1
公开(公告)日:2004-06-24
This invention is directed to prodrugs that can be activated at the preferred site of action in order to selectively deliver the corresponding therapeutic parent drugs to target cells or to the target site. This invention will therefore primarily but not exclusively relate to tumor cells as target cells. More specifically the prodrugs are compounds of the formula V—(W)k-(X)l-A-Z, wherein: V is a specifier; (W)k-(X)l-A is an elongated self-elimination spacer system; W and X are each a l,(4+2n) electronic cascade spacer, being the same or different; A is either a spacer group of formula (Y) m wherein: Y is a l,(4+2n) electronic cascade spacer, or a group of formula U being a cyclisation elimination spacer; Z is a therapeutic drug; k, l and m are integers from 0 (included) to 5 (included); n is an integer of 0 (included) to 10 (included), with the provisos that:—when A is (Y)m: k+l+m
1, and if k+l+m=1;—when A is U: k+l
1.
本发明涉及一种前药,可以在优选的作用部位被激活,以有选择地将相应的治疗原药物递送到靶细胞或靶部位。因此,本发明主要但不仅限于与肿瘤细胞作为靶细胞相关。更具体地说,前药是公式V—(W)k-(X)l-A-Z的化合物,其中:V是说明符;(W)k-(X)l-A是一个延长的自我消除间隔系统;W和X分别是l,(4+2n)电子级联间隔器,可以相同也可以不同;A是公式(Y)m的间隔基,其中:Y是l,(4+2n)电子级联间隔器,或者是公式U的基团,是一个环化消除间隔器;Z是治疗药物;k、l和m是从0(包括)到5(包括)的整数;n是0(包括)到10(包括)的整数,但限制条件是:当A是(Y)m时:k+l+m≥1,如果k+l+m=1;当A是U时:k+l≥1。